• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

    5/12/25 10:24:40 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    ABSCI CORP

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    00091E109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00091E109


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    18,384,670.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    18,386,848.82
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,386,848.82
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    00091E109


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    18,386,848.82
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    18,386,848.82
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ABSCI CORP
    (b)Address of issuer's principal executive offices:

    18105 SE MILL PLAIN BLVD,VANCOUVER,WA,USA,98683
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    00091E109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    18386848.82
    (b)Percent of class:

    14.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    18386848.82

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ABSCI CORP. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of ABSCI CORP, amounted to 7810292.00 shares or 6.1% of the total outstanding COMMON STOCK at 03/31/2025.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/09/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:05/09/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $ABSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    7/18/2022$8.00Buy
    Truist
    More analyst ratings

    $ABSI
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

      SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)

      5/12/25 10:24:40 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Absci Corporation

      SCHEDULE 13D/A - Absci Corp (0001672688) (Subject)

      4/29/25 9:31:04 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by Absci Corporation

      DEFA14A - Absci Corp (0001672688) (Filer)

      4/28/25 4:13:02 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

      Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

      1/10/24 7:30:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

      VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

      6/6/23 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Welcomes Meta Senior Executive to Board of Directors

      VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the newest member of its Board of Directors. With three decades of leadership in scaling technologies, innovating business models and growing companies, Mr. Rabinovitsj will provide strategic insights as Absci continues to scale its unprecedented combination of AI and wet lab capabilities to help create better biologics for patients, faster. "Absci has impressed me with their technology and data, together which have the potential to turn Absci's bold vision into reality: to create therapeutics at a

      11/2/22 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Participate in Upcoming Investor Conferences

      VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time Interested parties may access live and archived webcasts of the fireside chat sessions on the company's

      3/26/25 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Financials

    Live finance-specific insights

    See more
    • Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

      VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

      4/14/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results

      Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full

      3/18/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

      VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available fo

      3/4/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Walker Shelby J. was granted 59,300 shares (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:43:06 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SVP, CAO Bedrick Todd was granted 29,700 shares, increasing direct ownership by 22% to 167,827 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:42:16 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Executive Officer Mcclain Sean was granted 190,200 shares, increasing direct ownership by 2% to 8,384,621 units (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/4/25 5:41:15 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Absci Corporation with a new price target

      Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

      1/22/25 7:30:02 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Guggenheim initiated coverage on Absci Corporation with a new price target

      Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00

      10/2/24 7:13:36 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Morgan Stanley initiated coverage on Absci Corporation with a new price target

      Morgan Stanley initiated coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

      7/3/24 7:24:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/5/24 9:30:43 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Absci Corporation

      SC 13G - Absci Corp (0001672688) (Subject)

      11/14/24 4:02:50 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Absci Corporation

      SC 13G/A - Absci Corp (0001672688) (Subject)

      11/12/24 9:50:12 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Absci Corporation (Amendment)

      SC 13D/A - Absci Corp (0001672688) (Subject)

      3/5/24 5:15:30 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care